# Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

> **NCT03892525** · PHASE1 · TERMINATED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 4 (actual)

## Conditions studied

- Recurrent B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Selicrelumab
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03892525
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-04
- **Primary completion:** 2021-04-07
- **Final completion:** 2021-04-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** End of drug development
- **Last updated:** 2021-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03892525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03892525, "Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03892525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*